VCAM1 and COVID-19: These results suggest that, among these biomarkers above, serum VCAM-1 concentrations and ACE2 activity were highly modulated by COVID-19 clinical status in response to vascular inflammation and pulmonary dysfunction, while enhanced platelet reactivity and lipid peroxidation did not substantially affect these vascular markers in our subjects.